These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35740400)

  • 1. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.
    Moreau M; Carmona-Iragui M; Altuna M; Dalzon L; Barroeta I; Vilaire M; Durand S; Fortea J; Rebillat AS; Janel N
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
    Dowjat K; Adayev T; Wojda U; Brzozowska K; Barczak A; Gabryelewicz T; Hwang YW
    J Alzheimers Dis; 2019; 72(4):1059-1075. PubMed ID: 31683476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased plasma DYRK1A with aging may protect against neurodegenerative diseases.
    Delabar JM; Lagarde J; Fructuoso M; Mohammad A; Bottlaender M; Doran E; Lott I; Rivals I; Schmitt FA; Head E; Sarazin M; Potier MC
    Transl Psychiatry; 2023 Apr; 13(1):111. PubMed ID: 37015911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
    Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
    Hijazi M; Fillat C; Medina JM; Velasco A
    Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma DYRK1A as a novel risk factor for Alzheimer's disease.
    Janel N; Sarazin M; Corlier F; Corne H; de Souza LC; Hamelin L; Aka A; Lagarde J; Blehaut H; Hindié V; Rain JC; Arbones ML; Dubois B; Potier MC; Bottlaender M; Delabar JM
    Transl Psychiatry; 2014 Aug; 4(8):e425. PubMed ID: 25116835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease.
    de Souza MM; Cenci AR; Teixeira KF; Machado V; Mendes Schuler MCG; Gonçalves AE; Paula Dalmagro A; André Cazarin C; Gomes Ferreira LL; de Oliveira AS; Andricopulo AD
    Curr Med Chem; 2023; 30(6):669-688. PubMed ID: 35726411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
    Dowjat K; Adayev T; Kaczmarski W; Wegiel J; Hwang YW
    J Neuropathol Exp Neurol; 2012 Dec; 71(12):1100-12. PubMed ID: 23147510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome.
    Videla L; Benejam B; Pegueroles J; Carmona-Iragui M; Padilla C; Fernández S; Barroeta I; Altuna M; Valldeneu S; Garzón D; Ribas L; Montal V; Arranz Martínez J; Rozalem Aranha M; Alcolea D; Bejanin A; Iulita MF; Videla Cés S; Blesa R; Lleó A; Fortea J
    JAMA Netw Open; 2022 Aug; 5(8):e2225573. PubMed ID: 35930282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.